Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 5, 2002, Pages 334-348

  Mould, Diane R ^a   Holford, Nicholas H G ^a   Schellens, Jan H M ^a   Beijnen, Jos H ^b   Hutson, Paul R ^c   Rosing, Hilde ^d   Ten Bokkel Huinink, Willem W ^e   Rowinsky, Eric K ^e   Schiller, Joan H ^f   Russo, Mark ^f   Ross, Graham ^f  

^a DIVISION OF REPRODUCTIVE BIOLOGY   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c RESEARCH AND DEVELOPMENT   (Australia)

^d College of Chemistry and Molecular Engineering ^*  (China)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f Projections Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG CLEARANCE; FEMALE; HUMAN; INDIVIDUALIZATION; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CONFIDENCE INTERVALS; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; NEUTROPENIA; PROBABILITY; TOPOTECAN;

EID: 18344394148     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.123553     Document Type: Article

References (38)

1. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
2. Phase I pharmacokinetics study of topotecan, a new topoisomerase inhibitor
3. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
4. Clinical pharmacokinetics of topotecan
5. An overview of the clinical pharmacology of topotecan
6. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer
7. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
8. Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity
9. Phase I and pharmacologic studies of topotecan in patients with impaired renal function
10. Topotecan drug monograph
11. Population pharmacokinetics of topotecan: Intraindividual pharmacokinetics variability of topotecan
12. Population pharmacokinetic model for topotecan derived from phase I clinical data
13. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion
14. O-Glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan
15. Phase I pharmacologic study of topotecan in patients with impaired renal function
16. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
17. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial
18. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
19. An open label multicentre, randomised, phase II comparator study of oral topotecan versus intravenous topotecan for second line therapy in sensitive patients with small cell lung cancer
20. A multicentre, randomised, phase III study of topotecan administered intravenously or oral for advanced epithelial ovarian cancer
21. Phase I study of topotecan and thoracic radiation
22. The pharmacokinetics and pharmacodynamics of topotecan
23. Prediction of creatinine clearance from serum creatinine
24. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily
25. Assumption testing in population pharmacokinetic models: Illustrated with an analysis of moxonidine data from congestive heart failure patients
26. High performance liquid chromatographic analysis of the new antitumour agent SK&F 104864-A (NSC 609699) in plasma
27. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma
28. A size standard for pharmacokinetics
29. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients
30. Xpose - An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
31. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials
32. Regression models for ordinal data
33. Population pharmacodynamic model for keterolac analgesia
34. Bootstrap approach for construction of confidence intervals for population pharmacokinetic parameters. I. A use of bootstrap standard error
35. Bayesian individualization of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods
36. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
37. Clinical guidelines for managing topotecan-related hematological toxicity